A Japanese study found that weekly paclitaxel was safe and well-tolerated among patients with anaplastic thyroid carcinoma, a notoriously aggressive malignancy.
ATA Thyroid Cancer 2015
The coexistence of mutations in telomerase reverse transcriptase (TERT) and BRAF genes dramatically increases the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths.
Immune checkpoint inhibitor therapy is looking increasingly plausible as a potential investigative strategy for treating thyroid cancers.
New ATA Guidelines offer clear and welcome guidance against routine post-thyroidectomy remnant tumor ablation with radioactive iodine, agreed experts at the 85th Annual Meeting of the ATA.
Researchers in Germany appear to have identified a gene-expression signature associated with metastasis in sporadic medullary thyroid cancer and prognostic molecular tumor markers of medullary thyroid cancer response to vandetanib therapy.
For patients who can tolerate aggressive multimodal therapy for anaplastic thyroid carcinoma, survival rates can exceed historical outcomes, according to a retrospective study of patients treated at the Mayo Clinic.
It is too soon to determine the influence of radiation exposure on thyroid cancer risk among children and adolescents exposed to the 2011 Fukushima Daiichi nuclear power plant disaster in Japan, according to the lead author of findings presented at the 85th Annual Meeting of the ATA.
Preclinical findings suggest that autophagy inhibition might prove useful in overcoming BRAF-mutant thyroid cancers resistant to vemurafenib.
The FAM83F protein contributes to papillary thyroid cancer cell viability and doxorubicin resistance, according to a study presented at the 85th Annual Meeting of the ATA.
Release of newly revised, evidence-based clinical management guidelines for thyroid nodules and differentiated thyroid cancers were announced at the 85th Annual Meeting of the ATA.